pharma · Phenylketonuria · Achondroplasia
BioMarin Pharmaceutical Australia Pty Ltd
BioMarin Pharmaceutical Australia is a pharma organization headquartered in San Rafael, USA. Primary therapeutic focus areas include Phenylketonuria, Achondroplasia, Duchenne Muscular Dystrophy, Phenylketonuria (PKU), Hy
Phase 2 · small molecule · Hypochondroplasia
Voxzogo (vosoritide) 0.56 mg is a subcutaneous injection developed by BioMarin Pharmaceutical Australia Pty Ltd for the treatment of hypochondroplasia, a genetic skeletal dysplasia characterized by short stature. The drug is a small-molecule therapeutic targeting the musculo-skeletal system. Voxzogo has achieved regula
Internal code 111-212
Voxzogo (vosoritide) 0.56 mg is a subcutaneous injection developed by BioMarin Pharmaceutical Australia Pty Ltd for the treatment of hypochondroplasia, a genetic skeletal dysplasia characterized by short stature. The drug is a small-molecule therapeutic targeting the musculo-skeletal system. Voxzogo has achieved regulatory approval in Australia (May 2023), the European Union (November 2025), and the United States, indicating successful completion of pivotal trials and regulatory review. The program is currently in Phase 2 development, with an active trial (NCT 2024-512261-14-00) evaluating safety and efficacy in infants and young children aged 0 to less than 36 months. This pediatric-focused trial represents BioMarin's strategy to establish early clinical evidence in the youngest patient population, potentially supporting label expansion and long-term treatment paradigms. The approvals across major markets demonstrate regulatory confidence in the drug's benefit-risk profile for this rare genetic disorder.
Hypochondroplasia is a rare genetic skeletal dysplasia affecting longitudinal bone growth, resulting in short stature and associated complications. The condition represents an unmet medical need with limited therapeutic options historically available to patients. Voxzogo's approval marks a significant advancement in disease-modifying therapy for this population, offering a mechanism-based approach to address the underlying pathophysiology rather than symptomatic management alone. The drug's approval across Australia, the EU, and the US within a concentrated timeframe indicates strong regulatory recognition of clinical benefit in a pediatric population with few alternatives. The competitive landscape includes bone metabolism agents (bisphosphonates, denosumab, romosozumab) and other skeletal therapies, but these are not specifically indicated for hypochondroplasia. Voxzogo's market relevance is anchored to the rare disease population, with commercial significance driven by orphan drug designation, premium pricing potential, and the pediatric indication. The Phase 2 trial in infants and young children (0–36 months) addresses a critical clinical question regarding early intervention, potentially expanding the addressable patient population and establishing treatment paradigms in the youngest patients, which could drive long-term market penetration and patient lifetime value.
Drug Class: Musculo-skeletal system therapeutic (ATC M05)
Modality: Small molecule
Route of Administration: Subcutaneous injection
Mechanism of Action: Not disclosed in available facts
Target: Not disclosed in available facts
Formulation: Powder and solvent for solution for injection, 0.56 mg strength
Related Therapies: Voxzogo 1.2 mg formulation (Phase 3 development by BioMarin); competitive agents in musculo-skeletal disease include bisphosphonates (ibandronic acid, alendronic acid), denosumab (Vysribli), romosozumab (Evenity), and other bone-targeting agents
First Approval: Australia (May 2023); European Union (November 2025); United States (date not specified but NDA 214938 approved)
Patent Status: Not disclosed
Also known as: HCH
Prevalence: Point prevalence: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
Hypochondroplasia is characterized by disproportionate short stature, mild lumbar lordosis and limited extension of the elbow joints.
ClinicalTrials.gov lists 11 registered studies for Hypochondroplasia (AACT aggregate).
Phase breakdown: NA (5), PHASE2 (3), PHASE3 (2), PHASE2/PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0007793), Orphanet — hypochondroplasia, NCT01111019, NCT01541306, NCT05328050, NCT06212947, NCT06410976, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Australian TGA Approval
Voxzogo 0.56 mg approved in Australia; listed on ARTG with PBS codes 13270K, 13274P, 13275Q.
European EMA Approval
Voxzogo approved by European Medicines Agency (EMEA/H/C/005475); MAH BioMarin International Limited.
US FDA Approval
Voxzogo approved in the United States under NDA 214938; sponsor BIOMARIN PHARM.
Phase 2 Pediatric Trial Active
Randomized, double-blind, placebo-controlled, multicenter Phase 2 study evaluating safety and efficacy in infants and young children with hypochondroplasia aged 0 to <36 months (NCT 2024-512261-14-00).
The competitive landscape for Voxzogo in the musculo-skeletal disease space includes several approved agents, though few are specifically indicated for hypochondroplasia. Bisphosphonates such as Ibandronic Acid Sandoz (Teva Pharma) and Alendronic Acid/Colecalciferol Mylan represent older, non-specific bone metabolism modifiers. Monoclonal antibody-based therapies include Denosumab (Vysribli, previously Intas formulation) and Romosozumab (Evenity, Amgen), which target bone remodeling through different mechanisms. Amgen's Corora and Evenity represent newer-generation agents in bone health. Crysvita (KYOWA KIRIN AUSTRALIA) targets a different rare skeletal disorder (X-linked hypophosphatemia). Bone morphogenetic protein-based therapies (Inductos, Osseor, Osigraft) address specific surgical and regenerative indications. Notably, Voxzogo appears to be the only approved disease-modifying therapy specifically for hypochondroplasia, positioning it as a category-defining agent with limited direct competition in its indication. BioMarin's pipeline includes a higher-strength formulation (Voxzogo 1.2 mg) in Phase 3, suggesting dose optimization and potential label expansion strategies. The competitive advantage lies in mechanism specificity for the hypochondroplasia indication rather than broad bone metabolism targeting.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| IBANDRONIC ACID SANDOZ | Teva Pharma GmbH | — | approved |
| CORORA | Amgen | — | approved |
| ACLASTA | Apotex Pty Ltd | — | approved |
| CRYSVITA | KYOWA KIRIN AUSTRALIA PTY LTD | — | approved |
| OSIGRAFT | — | — | approved |
| EVENITY | Amgen | — | approved |
| OSSEOR | — | — | approved |
| ALENDRONIC ACID / COLECALCIFEROL MYLAN | — | — | approved |
| VYSRIBLI (PREVIOUSLY DENOSUMAB INTAS) | — | — | approved |
| VANTAVO (PREVIOUSLY ALENDRONATE SODIUM AND COLECALCIFEROL, MSD) | — | — | approved |
| INDUCTOS | — | — | approved |
| Voxzogo 1.2 mg powder and solvent for solution for injection, powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection | BioMarin Pharmaceutical Australia Pty Ltd | small_molecule | phase_3 |
| VOSORITIDE | — | Atrial natriuretic peptide receptor B binding agent | Phase 3 |
| SOMATROPIN | — | Growth hormone receptor agonist | Phase 2 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States (FDA): Voxzogo approved under NDA 214938 (sponsor: BIOMARIN PHARM); approval date not specified in available facts.
European Union (EMA): Voxzogo approved November 17, 2025 (EMEA/H/C/005475); Marketing Authorization Holder: BioMarin International Limited.
Australia (TGA): Voxzogo 0.56 mg approved May 1, 2023; listed on ARTG with PBS codes 13270K, 13274P, 13275Q; sponsor BioMarin Pharmaceutical Australia Pty Ltd.
Japan (PMDA): Regulatory status not yet disclosed.
China (NMPA): Regulatory status not yet disclosed.
Orphan Drug Status: Not specified in available facts.
Patent Expiration: Not yet disclosed.
Voxzogo (vosoritide) is approved for the treatment of hypochondroplasia, a rare genetic skeletal dysplasia characterized by short stature and impaired longitudinal bone growth.
Yes, Voxzogo is approved in Australia (May 2023), the European Union (November 2025), and the United States. Regulatory status in Japan and China is not yet disclosed.
Voxzogo is developed and manufactured by BioMarin Pharmaceutical Australia Pty Ltd (Australia), with BioMarin International Limited as the Marketing Authorization Holder in the EU.
Voxzogo is administered as a subcutaneous injection. The 0.56 mg formulation is supplied as a powder and solvent for solution for injection.
The specific mechanism of action is not disclosed in available facts.
The specific molecular target is not disclosed in available facts.
Pivotal trial details are not specified in available facts. A Phase 2 trial (NCT 2024-512261-14-00) is currently active, evaluating safety and efficacy in infants and young children aged 0 to <36 months.
Voxzogo 0.56 mg is approved in three major markets and has an active Phase 2 trial in pediatric patients. A higher-strength formulation (1.2 mg) is in Phase 3 development.
Voxzogo is listed on the Australian Register of Therapeutic Goods (ARTG) with PBS codes 13270K, 13274P, and 13275Q.
The EMA product number is EMEA/H/C/005475, with authorization date November 17, 2025.
The US FDA New Drug Application (NDA) number is NDA214938, sponsored by BIOMARIN PHARM.
Voxzogo appears to be the only approved disease-modifying therapy specifically for hypochondroplasia. Broader bone metabolism agents (bisphosphonates, denosumab, romosozumab) are approved for other skeletal conditions but not specifically for hypochondroplasia.
Voxzogo is classified as a musculo-skeletal system therapeutic (ATC code M05).
Voxzogo is a small-molecule therapeutic.
The Phase 2 trial (NCT 2024-512261-14-00) is a randomized, double-blind, placebo-controlled, multicenter study evaluating safety and efficacy of vosoritide in infants and young children with hypochondroplasia aged 0 to <36 months.
Yes, BioMarin is developing Voxzogo 1.2 mg, which is currently in Phase 3 development.
Hypochondroplasia is a rare genetic skeletal dysplasia characterized by impaired longitudinal bone growth, resulting in short stature and associated skeletal complications.
111-212 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: BioMarin's approval of Voxzogo across three major markets (Australia, EU, US) within a concentrated timeframe signals successful execution of a rare disease commercialization strategy. The Phase 2 trial in infants aged 0–36 months represents a critical inflection point: establishing efficacy and safety in the youngest population could support label expansion to earlier treatment initiation, potentially creating a long-term treatment paradigm and increasing lifetime patient value. This early-intervention strategy differentiates Voxzogo from symptomatic-only approaches.
Competitive Implications: Voxzogo appears to occupy a unique niche as the only approved disease-modifying therapy for hypochondroplasia. The competitive set (bisphosphonates, denosumab, romosozumab) targets broader bone metabolism rather than the specific pathophysiology of this rare skeletal dysplasia. BioMarin's higher-strength formulation (1.2 mg, Phase 3) suggests dose optimization and potential for differentiated dosing strategies across age groups or disease severity.
Future Catalysts: Completion and readout of the Phase 2 pediatric trial (NCT 2024-512261-14-00) will be a key catalyst; positive results could support label expansion to younger age groups and establish early-intervention treatment paradigms. Phase 3 data for the 1.2 mg formulation may enable dose-ranging guidance and expanded indications. Regulatory approvals in Japan and China would significantly expand addressable market. Patent and exclusivity landscape developments will influence generic/biosimilar entry timing.
Expected Milestones: Phase 2 trial completion and data readout (date TBD); Phase 3 data for Voxzogo 1.2 mg (date TBD); potential label expansions or new indication filings; regulatory submissions in additional markets (PMDA, NMPA).
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.